This inventor holds 1 USPTO granted patent and 4 published patent applications. Top assignee: Genentech, Inc.. Active years: 2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2016
Title: Nathan McKnight: Innovator in Cell Culture Media and Antibody Production
Introduction
Nathan McKnight is a notable inventor based in South San Francisco, California. He has made significant contributions to the field of biotechnology, particularly in the development of cell culture media and methods for antibody production. His innovative work has implications for various applications in medical research and therapeutic development.
Latest Patents
Nathan McKnight holds a patent for "Cell culture media and methods of antibody production." This patent encompasses compositions of cell culture media and outlines methods for utilizing these media to produce antibodies from cells. The patent also includes compositions comprising antibodies and their fragments, produced through the methods described.
Career Highlights
Nathan McKnight is currently employed at Genentech, Inc., a leading biotechnology company known for its focus on developing innovative medicines. His work at Genentech has allowed him to contribute to groundbreaking advancements in the field of biotechnology.
Collaborations
Nathan collaborates with talented professionals in his field, including Veronica Carvalhal and Natarajan Vijayasankaran. These collaborations enhance the research and development efforts at Genentech, fostering an environment of innovation and discovery.
Conclusion
Nathan McKnight's contributions to cell culture media and antibody production exemplify the impact of innovation in biotechnology. His work continues to influence the development of new therapies and medical advancements.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
